Back to news
- emma.richards
- February 24th, 2026
Bowmed Ibisqus is pleased to announce the launch of Levobupivacaine IV, supplied as a pack of five clear glass ampoules. The product is available in three strengths: 25mg/10ml, 50mg/10ml, and 75mg/10ml, offering flexibility for a range of clinical applications.
Levobupivacaine is a long‑acting local anaesthetic and analgesic widely used for surgical anaesthesia—including epidural, intrathecal, and peripheral nerve block techniques—as well as for acute pain management. Please note the therapeutic indications for the 75mg/10ml presentation differs from the other strengths and refer to the SPC for details.
The ampoules are supplied in a non‑sterile‑wrapped tray, and if necessary, dilution should be carried out using sodium chloride 9mg/ml (0.9%) using aseptic techniques. Administration of Levobupivacaine should only be performed by, or under the supervision of, clinicians with the appropriate training and experience to ensure safe and effective use of the product.
The new products have been listed with AAH under codes LEV0344Q (25mg/10ml), LEV0343U (50mg/10ml), LEV0342B (75mg/10ml). Stock is available for customers effective immediately.
If you would like to discuss a pricing arrangement or stock availability for Levobupivacaine or any of our other products, please contact us directly on +44 (0)845 6436 703 or email us
Levobupivacaine-Flyer-V1Feb-26-Final-1.pdf
